NCT02759562View on ClinicalTrials.gov

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

November 4, 2016

Primary Completion Date

July 6, 2017

Study Completion Date

July 21, 2017

Conditions

Cystic Fibrosis

Interventions

DRUG

Andecaliximab

Administered via subcutaneous injection

DRUG

Placebo

Administered via subcutaneous injection

Trial Locations (5)

Unknown

New Lambton

Montpellier

Berlin

Barcelona

Liverpool

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY